Dual blocking of PI3K and mTOR signaling by DHW‐221, a novel benzimidazole derivative, exerts antitumor activity in human non‐small cell lung cancer.

GLO:F2H7/01sep21:ctm2514-fig-0001.jpg PHOTO (COLOR): 1 DHW-221 is a PI3K/mTOR dual-target inhibitor and inhibits the PI3K/AKT/mTOR signaling pathway. Dual blocking of PI3K and mTOR signaling by DHW-221, a novel benzimidazole derivative, exerts antitumor activity in human non-small cell lung cancer (E, G) Western blot was also used to evaluate the effects of DHW-221 on PI3K/AKT/mTOR pathway-related proteins in non-small cell lung cancer (NSCLC) cells and tissues (n = 6). We previously designed and synthesized a novel benzimidazole compound, DHW-221.1 Here, we evaluated its anti-NSCLC activity as a PI3K/mTOR dual-target inhibitor and comprehensively described for the first time the mechanism underlying the PI3K/AKT/mTOR signaling pathway-mediated antitumor effects of DHW-221. [Extracted from the article]